# Randomized, Double-blind, Placebo-Controlled Pilot Study of MDMA-assisted Therapy for PTSD

> **NCT01689740** · PHASE2 · COMPLETED · sponsor: **Resilient Pharmaceuticals** · enrollment: 10 (actual)

## Conditions studied

- Posttraumatic Stress Disorder (PTSD)

## Interventions

- **DRUG:** Active Placebo Dose MDMA-assisted therapy (25 mg)
- **DRUG:** Full Dose MDMA-assisted therapy (125 mg)
- **DRUG:** Open-Label Full Dose MDMA-assisted therapy (125 mg)
- **BEHAVIORAL:** Psychotherapy

## Key facts

- **NCT ID:** NCT01689740
- **Lead sponsor:** Resilient Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01-17
- **Primary completion:** 2016-04-07
- **Final completion:** 2017-07-16
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2025-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01689740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01689740, "Randomized, Double-blind, Placebo-Controlled Pilot Study of MDMA-assisted Therapy for PTSD". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01689740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*